Tung-Hu Tsai
Overview
Explore the profile of Tung-Hu Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
287
Citations
3822
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee W, Kung Y, Sun C, Chang C, Peng W, Lin L, et al.
Heliyon
. 2024 Aug;
10(15):e34820.
PMID: 39170551
Aim Of The Study: Our hypothesis is that nirmatrelvir can penetrate the blood‒brain barrier and reach effective concentrations in the brain. Furthermore, herbal formulations can help maintain nirmatrelvir levels in...
2.
Chang W, Chen Y, Lin C, Wang C, Shieh H, Chi C, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062140
Colon cancer has a poor clinical response to anti-PD1 therapy. This study aimed to evaluate the effect of cordycepin on the efficacy of anti-PD1 treatment in colon cancer. The viability...
3.
Sun C, Huang A, Hsueh T, Ting C, Lin L, Tsai T
J Pharm Biomed Anal
. 2024 Jun;
248:116285.
PMID: 38878452
Acetaminophen (APAP), or paracetamol, is one of the most widespread and commonly used non-prescription pain medication in the world, and is effective at managing wide range of pain, including headache,...
4.
Chan J, Chang Y, Chan H, Chan H, Chang W, Wang L, et al.
Mol Med
. 2024 May;
30(1):73.
PMID: 38822233
Human malignant pleural mesothelioma (hMPM) is an aggressive, rare disease with a poor prognosis. Histologically, MPM is categorized into epithelioid, biphasic, and sarcomatoid subtypes, with the epithelioid subtype generally displaying...
5.
Sun C, Kung Y, Lee W, Lin L, Yang M, Tsai T
J Pharm Biomed Anal
. 2024 Apr;
245:116162.
PMID: 38678857
Ritonavir, an excellent inhibitor of CYP3A4, has recently been combined with nirmatrelvir to form Paxlovid for the treatment of severe acute respiratory syndrome coronavirus 2 infections. The root of Scutellaria...
6.
Sun C, Lee W, Yang M, Tsai T
Heliyon
. 2024 Jan;
10(2):e24333.
PMID: 38293424
Background: Ritonavir is one of the most potent CYP3A4 inhibitor currently on the market, and is often used together with other antiviral drugs to increase their bioavailability and efficacy. Paxlovid,...
7.
Chang W, Wang C, Tsai T, Sun F, Chen C, Kuo K, et al.
Expert Rev Anti Infect Ther
. 2024 Jan;
22(7):587-595.
PMID: 38288986
Background: The aim of this study was to assess the efficacy and safety of NRICM101 in hospitalized patients with COVID-19. Research Design And Methods: We conducted a retrospective study from...
8.
Chang C, Peng W, Lee W, Yang L, Lin T, Yang M, et al.
Commun Med (Lond)
. 2023 Oct;
3(1):150.
PMID: 37857815
Background: The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19). However, there is very little...
9.
Chang C, Peng W, Lee W, Lin T, Yang M, Dalley J, et al.
EBioMedicine
. 2023 Aug;
95:104748.
PMID: 37544201
Background: Molnupiravir is an orally bioavailable prodrug of the nucleoside analogue β-D-N4-hydroxycytidine (NHC) and is used to treat coronavirus disease 2019 (COVID-19). However, the pharmacokinetics and transplacental transfer of molnupiravir...
10.
Chang C, Peng W, Lee W, Lin T, Yang M, Dalley J, et al.
J Pharm Biomed Anal
. 2023 Jun;
234:115499.
PMID: 37302376
The aim of this study was to explore the effects of herbal drug pharmacokinetic interactions on the biotransformation of molnupiravir and its metabolite β-D-N4-hydroxycytidine (NHC) in the blood and brain....